Dose Intensity/Body Surface Area Ratio Is a Novel Marker Useful for Predicting Response to Lenvatinib Against Hepatocellular Carcinoma

Cancers - Switzerland
doi 10.3390/cancers12010049
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Usefulness of Dose Intensity/Body Surface Area Ratio (DI/BSA Ratio; DBR) Rather Than Relative Dose Intensity in the Lenvatinib Treatment for Hepatocellular Carcinoma

Acta Hepatologica Japonica
Hepatology
2020English

USP22 Is Useful as a Novel Molecular Marker for Predicting Disease Progression and Patient Prognosis of Oral Squamous Cell Carcinoma

PLoS ONE
Multidisciplinary
2012English

SAC3D1: A Novel Prognostic Marker in Hepatocellular Carcinoma

Scientific Reports
Multidisciplinary
2018English

Lrig1 Is a Positive Prognostic Marker in Hepatocellular Carcinoma

OncoTargets and Therapy
OncologyPharmacology
2016English

ASPM Is a Novel Marker for Vascular Invasion, Early Recurrence, and Poor Prognosis of Hepatocellular Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2008English

SOX9 Is a Novel Cancer Stem Cell Marker Surrogated by Osteopontin in Human Hepatocellular Carcinoma

Scientific Reports
Multidisciplinary
2016English

Is Higher Dose Always the Right Answer in Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma?

Radiation Oncology Journal
OncologyRadiologyNuclear MedicineImaging
2018English

The Three Criteria for Radiological Response on Survival in Patients With Hepatocellular Carcinoma Treated With Lenvatinib

Hepatology Research
HepatologyInfectious Diseases
2019English

Carnitine Insufficiency Is Associated With Fatigue During Lenvatinib Treatment in Patients With Hepatocellular Carcinoma

PLoS ONE
Multidisciplinary
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy